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  Fifteen cases of advanced prostatic cancer （mostly stages C and D） were treated with Estracyt
（KES－504， Estramustine phosphate， 560 mg daily in two dlvided deses） and clinical findings as well
as laboratory and endocrine effects were recorded． The study subjects consisted of two groups， i．e．，
group 1 with untreated patients and group II with hormone resistant patients who had been subjected
to previous antiandregenic therapy． Subjective and objective effects were observed to be more favo－
rable in group 1． patients compared to group I I subjects， as far as could be judged from results obtained
in the observation peri．od of 3 to 6 months．
  Decreases in serum levels of LH， FSH and testosterone were observed shortly after the commence－
ment of clrug administration． lt was concluded that Estracyt exerted clinical effects in these patients
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投 与 方 法




検 討 項 目
 D 自覚症状
 本剤投与経過中において自覚症状について判定しt：





  Table 2．
試験1
自覚症状におよぼす効果









































































  Table 3．
試験1
他覚所見における効果
残 尿 量 前立腺触診所見
50％以上減少  2
不  変    2
増  加    0
縮 小  4
不 変  2
増 大  0
試験n
残 尿 量 前立腺触診所見
50％以L減少  2
不  変    4
増  加    1
縮 小  1
不 変  5
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Photo・3・症例6における前立腺生検像（治療前）
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